New Studies Support Case for Bisphosphonates as Possible Chemopreventive Agent

C. Schmidt
2010 Journal of the National Cancer Institute  
A ttendants at the San Antonio Breast Cancer Symposium in December were treated to a remarkable coincidence: two scientists, each unaware of the other's research, reporting the same findings in backto-back presentations. Rowan Chlebowski, M.D., Ph.D., from the University of California, Los Angeles, and Gad Rennert, M.D., Ph.D., from the Technion-Israel Institute of Technology, in Haifa, both described evidence to suggest that bisphosphonate treatment for bone loss protects against breast cancer
more » ... in postmenopausal women. Chlebowski reviewed case data from the Women's Health Initiative -an investigation into causes of death and disability in postmenopausal women administered by the National Institutes of Health -and found statistically signifi cantly fewer diagnoses of breast cancer among women who take bisphosphonates than in those who do not. A total of 5,092 invasive breast cancers were diagnosed after 1,163,344 personyears of follow-up in women not using bisphosphonate (for a rate of 4.38/1,000 person-years). In women using bisphosphonates, 64 invasive breast cancers were
doi:10.1093/jnci/djq114 pmid:20339136 fatcat:gooparrjpzav3cwt4bgcbj3wiq